International Expert of Bone Tumor - Prof. Lehner's China Tour 2025 (1)

9月15日至17日，德国著名骨肿瘤专家Lehner教授访问南方医科大学第三附属医院。Lehner教授现任海德堡大学附属医院骨科与创伤外科骨肿瘤分科及感染性骨外科主任、海德堡认证肉瘤中心主任，在骨与软组织肿瘤领域享有盛誉。该院副院长王亮、骨肿瘤科李浩淼主任及团队共同为Lehner教授举行别开生面的欢迎仪式。在为期三天的工作中，Lehner教授与骨肿瘤团队开展了深入交流，通过门诊、查房、病例讨论、手术指导以及大师公开课等多种形式分享了中德双方在骨与软组织肿瘤手术治疗、肿瘤假体周围感染等方面的临床经验与技术进展。Lehner教授充分肯定该院人才储备和专业水平。李浩淼主任曾去传说中的意大利里佐利骨科研究所学习了一年。师从世界脊柱肿瘤大师Boriani 教授。2012年建科，13载精耕细作，每年1500台标志性手术。为每位病人提供定制化的专业服务。Lehner教授分享了未来骨肿瘤的科研与临床进展将更多聚焦于肿瘤内科方向。如放疗、化疗以及新型药物疗法，这将具有广阔的发展潜力。成立骨肿瘤内科团队更有助于持续跟进非手术治疗的前沿动态与治疗策略，为患者提供更全面的治疗方案。本次中德合作是南方医科大学第三附属医院骨肿瘤团队与海德堡大学附属医院一次高水平国际对话。中国医疗要发展，还是需要很多有雄心、有全球思考、有抱负、正直的医生，他们才是未来中国医疗的希望。

From September 15 to 17, Prof. Lehner, a renowned German expert in orthopedic oncology, visited the Southern Medical University Third Hospital. Prof. Lehner is the Director of the Section of Orthopedic Oncology and Septic Orthopedic Surgery of Clinic for Orthopedics at Heidelberg University Hospital, as well as the Head of Certified Sarcoma Center Heidelberg, with high influence and reputation in the field of bone and soft tissue tumors. A distinctive welcome ceremony was held for Prof. Lehner by Prof. WANG Liang, Vice Hospital President, Prof. LI Haomiao, the Director of the Department of Orthopedic Oncology and his team. During the three-day visit, Prof. Lehner engaged in in-depth exchanges with the host team. Both sides shared clinic experiences and technological advances in surgical treatment of bone and soft tissue tumors, as well as in managing tumor prosthesis-related periprosthetic infection through various activities such as joint outpatient consultation, joint ward rounds, cases discussions, operation observation and public lectures. Prof. Lehner spoke highly of the talent pool and the expertise of the host team. Prof. LI Haomiao had previously stayed at the Rizzoli Orthopaedic Institute in Italy for one year under the guidance of Prof. Boriani, a world-class master in spine tumor. Since its establishment in 2012, the department had been dedicated to excellence for 13 years, performs 1500 signature surgeries annually and provides customized professional care for each patient. Prof. Lehner noted that future research and clinical advences in bone tumors are expected to shift more toward medical oncology, including radiotherapy, chemotherapy and novel drug therapies, which hold broad potential for development. Establishing a dedicated bone tumor medical oncology team will facilitate continuous tracking of the latest developments and treatment strategies of non-surgery therapies, thereby providing patients with more comprehensive treatment options. The visit is a high-level international exchange between the orthopedic oncology team at Southern Medical University Third Hospital and Heidelberg University Hospital. The advancement of healthcare in China depends on doctors who have great ambition, global thinking, aspiration and integrit. They are the true future of Chinese healthcare.